Skip to main content
Guard Therapeutics International AB logo

Guard Therapeutics International AB — Investor Relations & Filings

Ticker · GUARD ISIN · SE0021181559 LEI · 549300DTX7T87FGYG180 ST Professional, scientific and technical activities
Filings indexed 0 across all filing types
Latest filing no filings yet
Country SE Sweden
Listing ST GUARD

About Guard Therapeutics International AB

https://guardtherapeutics.com/

Guard Therapeutics International AB is a clinical-stage biotechnology company focused on developing novel therapies for diseases with significant unmet medical needs, particularly kidney diseases. The company's research is centered on the endogenous protein Alpha-1-Microglobulin (A1M), which possesses cell-protective and antioxidative properties. Its lead drug candidate, RMC-035, is a recombinant form of A1M being developed as an intravenous treatment to prevent acute kidney injury. The candidate has been evaluated in a Phase 2b clinical trial (POINTER) in patients undergoing open-heart surgery, a procedure associated with a high risk of kidney complications.

Recent filings

No filings indexed yet

We are still gathering filings for Guard Therapeutics International AB. .

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.